bla	bla1	bla2	bla3	bla4	bla5	bla6
Rank	Title	Status	Study Results	Conditions	Interventions	Locations	URL
1	Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas	Recruiting	No Results Available	T Cell Lymphoma	Drug: Brentuximab Vedotin	The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States	https://ClinicalTrials.gov/show/NCT04334174